Australia - English - Department of Health (Therapeutic Goods Administration)

douglas pharmaceuticals australia pty ltd - acitretin, quantity: 25 mg - capsule, hard - excipient ingredients: titanium dioxide; microcrystalline cellulose; purified water; iron oxide red; sodium ascorbate; iron oxide yellow; gelatin; maltodextrin; sodium lauryl sulfate; propylene glycol; butan-1-ol; isopropyl alcohol; strong ammonia solution; iron oxide black; ethanol; shellac; sulfuric acid - acitretin may be used for the treatment of:,? severe intractable psoriasis in all its forms,? severe forms of disorders of keratinisation such as,- hyperkeratosis palmaris et plantaris,- pustulosis palmaris et plantaris,- ichthyosis,- keratosis follicularis (darier's disease),- lichen planus affecting the skin or the mucosae,- pityriasis rubra pilaris

Australia - English - Department of Health (Therapeutic Goods Administration)

coregas pty ltd - nitrous oxide, quantity: 100 % v/v - gas, medicinal - excipient ingredients: - indications: 1. general anaesthesia: when an inhalation anaesthetic is required, the administration is usually accompanied by simultaneous administration of a volatile agent such as halothane, ethrane, etc. 2. analgesia with oxygen: - relief from severe pain, usually in emergency situations, by inhalation with oxygen. - useful also in short-term procedures which inevitably involve pain, such as wound and burn dressing, wound debridement and suturing. administration with oxygen. - in dental work to provide short-term analgesia for tooth extraction and other brief procedures. administration with oxygen. 3. others: - occasionally as an insufflating agent in laparoscopy. - in cryosurgery as a refrigerant.

Australia - English - Department of Health (Therapeutic Goods Administration)

inova pharmaceuticals (australia) pty ltd - metoclopramide hydrochloride monohydrate, quantity: 10.537 mg (equivalent: metoclopramide hydrochloride, qty 10 mg) - tablet, uncoated - excipient ingredients: colloidal anhydrous silica; lactose monohydrate; pregelatinised maize starch; magnesium stearate; maize starch - indications as at 10 august 1994: adults (20 years and over): as an adjunct to x-ray examination of the stomach and duodenum. to assist in intestinal intubation. to control nausea and vomiting associated with the following conditions: intolerance to essential drugs possessing emetic properties; uraemia; radiation sickness; malignant disease; postoperative vomiting; labour; infectious diseases. there is no clear benefit in motion sickness or other labyrinth disturbances. intramuscular administration of maxolon facilitates the absorption of a range of drugs including the absorption of aspirin in people with migraine. maxolon has been found useful in the management of gastric retention after gastric surgery. maxolon may be useful in the treatment of diabetic gastroparesis of mild to moderate severity. once control of diabetes has been established by diet and/or insulin, maxolon should be discontinued. young adults and children: the use of maxolon in patients under 20 years should be restricted to the following s

Australia - English - Department of Health (Therapeutic Goods Administration)

alexion pharmaceuticals australasia pty ltd - sebelipase alfa, quantity: 2 mg/ml - injection, intravenous infusion - excipient ingredients: citric acid monohydrate; sodium citrate dihydrate; water for injections; albumin - kanuma (sebelipase alfa rce) is indicated for long-term enzyme replacement therapy (ert) in patients of all ages with lysosomal acid lipase deficiency (lal-d).

Australia - English - Department of Health (Therapeutic Goods Administration)

eris pharmaceuticals (australia) pty ltd - anastrozole -

Australia - English - Department of Health (Therapeutic Goods Administration)

inova pharmaceuticals (australia) pty ltd - metoclopramide hydrochloride, quantity: 5 mg/ml - injection, solution - excipient ingredients: sodium chloride; water for injections - indications as at 10 august 1994: adults (20 years and over): as an adjunct to x-ray examination of the stomach and duodenum. to assist in intestinal intubation. to control nausea and vomiting associated with the following conditions: intolerance to essential drugs possessing emetic properties; uraemia; radiation sickness; malignant disease; postoperative vomiting; labour; infectious diseases. there is no clear benefit in motion sickness or other labyrinth disturbances. intramuscular administration of maxolon facilitates the absorption of a range of drugs including the absorption of aspirin in people with migraine. maxolon has been found useful in the management of gastric retention after gastric surgery. maxolon may be useful in the treatment of diabetic gastroparesis of mild to moderate severity. once control of diabetes has been established by diet and/or insulin, maxolon should be discontinued. young adults and children: the use of maxolon in patients under 20 years should be restricted to the following s

Australia - English - Department of Health (Therapeutic Goods Administration)

takeda pharmaceuticals australia pty ltd - lanadelumab, quantity: 300 mg - injection, solution - excipient ingredients: citric acid monohydrate; water for injections; dibasic sodium phosphate dihydrate; polysorbate 80; histidine; sodium chloride - takhzyro is indicated for routine prevention of recurrent attacks of hereditary angioedema (c1-esterase-inhibitor deficiency or dysfunction) in patients aged 12 years and older.

Australia - English - Department of Health (Therapeutic Goods Administration)

jazz pharmaceuticals anz pty ltd - defibrotide, quantity: 200 mg - injection, concentrated - excipient ingredients: hydrochloric acid; sodium citrate dihydrate; sodium hydroxide; water for injections - defitelio is indicated for the treatment of severe hepatic veno-occlusive disease (vod) also known as sinusoidal obstruction syndrome (sos) in haematopoietic stem-cell transplantation (hsct) therapy.,it is indicated in adults and in adolescents, children and infants of 1 month of age and above.

Australia - English - Department of Health (Therapeutic Goods Administration)

biomarin pharmaceutical australia pty ltd - cerliponase alfa, quantity: 30 mg/ml - injection, solution - excipient ingredients: dibasic sodium phosphate heptahydrate; sodium chloride; potassium chloride; magnesium chloride hexahydrate; calcium chloride dihydrate; water for injections; monobasic sodium phosphate monohydrate - brineura is indicated for the treatment of neuronal ceroid lipofuscinosis type 2 (cln2) disease, also known as tripeptidyl peptidase 1 (tpp1) deficiency.

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

amgrow pty ltd - bacillus thuringiensis subsp. israelensis serotype h14 - aqueous suspension - bacillus thuringiensis subsp. israelensis serotype h14 biological-organism-bt-israele active 0.0 u - insecticide - ditch | flood water | irrigation water | sewage settling pond | stagnant pond | standing water | tidal water saltmarsh | water - - australian house mosquito | brown house mosquito | common australian mosquito | common banded mosquito | domestic container mosquito | mosquito larva | saltmarsh culex | saltmarsh mosquito - larva | aedes notoscriptus | ochlerotatus vigilax